No quarterly revenue total was found in LB Pharmaceuticals Inc's SEC filings.
LB Pharmaceuticals Inc (LBRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$64.4 million. As of Sep 30, 2026 it held $403.8 million in cash and investments and $5.2 million in total debt.
Revenue
—
Net income
$-59.07M
-1561.0% vs year-ago quarter
Operating cash flow
$-64.29M
-275.9% vs year-ago quarter
Free cash flow
$-64.36M
-276.0% vs year-ago quarter
EPS
$-1.79
-193.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
32.36M
+27.9% vs year-ago quarter
Net cash
$398.60M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1691082
- Former names
- LB PHARMACEUTICALS INC. (until Dec 12, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$59.1M | -$51.6M | -$19.1M | -$11.5M | -$3.6M |
| Diluted EPS | -$1.79 | -$1.71 | -$0.67 | $0.54 | -$0.61 |
| Operating cash flow | -$64.3M | -$37.6M | -$23.3M | -$18.1M | -$17.1M |
| Free cash flow | -$64.4M | -$38.0M | -$23.3M | -$18.1M | -$17.1M |
| Total assets | $453.4M | $361.7M | $393.5M | $312.9M | $320.7M |
| Total liabilities | $35.7M | $29.3M | $14.8M | $11.6M | $10.5M |
| Stockholders' equity | $417.6M | $332.3M | $378.7M | $301.3M | $310.2M |
| Cash and investments | $403.8M | $327.8M | $365.6M | $295.2M | $314.5M |
| Total debt | $5.2M | $5.2M | $3.5M | $3.6M | $3.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
All 143 LB Pharmaceuticals Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.